Denali therapeutics announces $500 million private placement equity financing

South san francisco, calif., feb. 27, 2024 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today announced that the company has entered into a securities purchase agreement with certain existing accredited investors to issue and sell an aggregate of 3,244,689 shares of its common stock at a price of $17.07 per share and pre-funded warrants to purchase 26,046,065 shares of common stock at a purchase price of $17.06 per pre-funded warrant share, through a private investment in public equity (pipe) financing. the pre-funded warrants will have an exercise price of $0.01 per share of common stock, be immediately exercisable, and remain exercisable until exercised in full. denali anticipates the gross proceeds from the pipe to be approximately $500 million. the financing is expected to close on february 29, 2024, subject to customary closing conditions. proceeds from the financing are expected to be used to support denali's ongoing research and development activities, the acceleration and expansion of its proprietary bbb-crossing transport vehicle (tv) technology, as well as general corporate purposes and working capital.
DNLI Ratings Summary
DNLI Quant Ranking